Hexarelin

01 What is Hexarelin?

Hexarelin is a synthetic hexapeptide growth hormone secretagogue — and it is the most potent of its class for acute GH release. A single injection can produce GH spikes rivalling those seen with direct GH injection or insulin tolerance tests. For researchers studying the GH axis, it is a powerful pharmacological tool. For biohackers, it is a double-edged sword. The catch with Hexarelin is desensitisation. Unlike Sermorelin or Tesamorelin (which work through GHRH receptors and maintain response with chronic use), Hexarelin works through the ghrelin/GHS-R1a receptor — and this receptor downregulates quickly with repeated exposure. After 4-8 weeks of daily use, GH response diminishes significantly. You essentially wear out the receptor. This makes Hexarelin better suited for short-term, targeted use — burst protocols for injury healing, post-surgery recovery, or as a diagnostic tool — rather than long-term anti-ageing. Some practitioners cycle it (2-4 weeks on, 4 weeks off) to maintain receptor sensitivity, but even this approach may lose efficacy over time.

02 How Does It Work?

Hexarelin binds the Growth Hormone Secretagogue Receptor (GHS-R1a) — the same receptor that ghrelin activates. This triggers: 1. Direct pituitary GH release — massive acute spike (highest of any GH peptide). 2. Hypothalamic GHRH release — amplifying the pituitary signal. 3. Suppression of somatostatin — removing the brake on GH release. 4. Cardiac protective effects — GHS-R1a is expressed on cardiac tissue; Hexarelin has shown cardioprotective properties independent of GH release. The triple mechanism (direct pituitary + GHRH increase + somatostatin suppression) explains why GH response is so dramatic. But GHS-R1a desensitisation limits chronic utility.

03 What Does The Research Say?

GH release: Extensively studied. Produces 2-3x the GH release of GHRP-6 or GHRP-2 in head-to-head comparisons. Peak GH occurs 15-30 minutes post-injection. Cardioprotective: Animal and human studies show reduced cardiac fibrosis, improved cardiac function post-MI, and protection against ischaemia-reperfusion injury — independent of GH. This is a unique property among GH secretagogues. Desensitisation: Well-documented. GH response decreases by 50%+ after 4-8 weeks of daily use. Partial recovery after washout periods. No FDA approval. Used primarily in research and off-label clinical settings.

04 Reported Dosages

Subcutaneous: 100-200mcg 1-3 times daily (before meals or before bed). Short cycles recommended: 2-4 weeks maximum, then equal time off. Some protocols: 200mcg twice daily for injury recovery (2 weeks). Best on empty stomach (30 min before food). DISCLAIMER: Research peptide — not approved for human use. Desensitisation is real — do not use chronically. Some users combine with CJC-1295 to maintain response, but this adds complexity and unknowns.

05 Side Effects & Risks

Acute: intense hunger spike (ghrelin receptor activation), water retention, tingling/numbness (paraesthesia), cortisol and prolactin elevation (more than other GHRPs). Hexarelin raises prolactin and cortisol more than GHRP-2 or Ipamorelin. Chronic: receptor desensitisation (loss of efficacy), potential prolactin-related issues with extended use (gynaecomastia, libido changes in men). The cortisol/prolactin elevation makes it less 'clean' than Ipamorelin.

06 Legal Status